Your browser doesn't support javascript.
Serological responses to COVID-19 Comirnaty booster vaccine, London, United Kingdom, September to December 2021.
Ireland, Georgina; Whitaker, Heather; Ladhani, Shamez N; Baawuah, Frances; Subbarao, Sathyvani; Linley, Ezra; Warrener, Lenesha; O'Brien, Michelle; Whillock, Corinne; Martin, Oliver; Moss, Paul; Ramsay, Mary E; Amirthalingam, Gayatri; Brown, Kevin E.
  • Ireland G; Immunisation and Vaccine Preventable Diseases Division, UK Health Security Agency, London, United Kingdom.
  • Whitaker H; Statistics, Modelling and Economics Department, UK Health Security Agency, London, United Kingdom.
  • Ladhani SN; Immunisation and Vaccine Preventable Diseases Division, UK Health Security Agency, London, United Kingdom.
  • Baawuah F; Paediatric Infectious Diseases Research Group, St. George's University of London, London, United Kingdom.
  • Subbarao S; Immunisation and Vaccine Preventable Diseases Division, UK Health Security Agency, London, United Kingdom.
  • Linley E; Brondesbury Medical Centre, Kilburn, London, United Kingdom.
  • Warrener L; Immunisation and Vaccine Preventable Diseases Division, UK Health Security Agency, London, United Kingdom.
  • O'Brien M; Sero-Epidemiology Unit, UK Health Security Agency, Manchester, United Kingdom.
  • Whillock C; Virus Reference Department, UK Health Security Agency, London, United Kingdom.
  • Martin O; Brondesbury Medical Centre, Kilburn, London, United Kingdom.
  • Moss P; Immunisation and Vaccine Preventable Diseases Division, UK Health Security Agency, London, United Kingdom.
  • Ramsay ME; Immunisation and Vaccine Preventable Diseases Division, UK Health Security Agency, London, United Kingdom.
  • Amirthalingam G; Institute of Immunology and Immunotherapy, University of Birmingham, Edgbaston, United Kingdom.
  • Brown KE; Immunisation and Vaccine Preventable Diseases Division, UK Health Security Agency, London, United Kingdom.
Euro Surveill ; 27(1)2022 01.
Article in English | MEDLINE | ID: covidwho-1613512
ABSTRACT
Serum samples were collected pre- and post-booster vaccination with Comirnaty in 626 participants (aged ≥ 50 years) who had received two Comirnaty doses < 30 days apart, two Comirnaty doses ≥ 30 days apart or two Vaxzevria doses ≥ 30 days apart. Irrespective of primary vaccine type or schedule, spike antibody GMTs peaked 2-4 weeks after second dose, fell significantly ≤ 38 weeks later and rose above primary immunisation GMTs 2-4 weeks post-booster. Higher post-booster responses were observed with a longer interval between primary immunisation and boosting.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Vaccines / COVID-19 Type of study: Experimental Studies Topics: Vaccines Limits: Humans Country/Region as subject: Europa Language: English Journal subject: Communicable Diseases Year: 2022 Document Type: Article Affiliation country: 1560-7917.Es.2022.27.1.2101114

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Vaccines / COVID-19 Type of study: Experimental Studies Topics: Vaccines Limits: Humans Country/Region as subject: Europa Language: English Journal subject: Communicable Diseases Year: 2022 Document Type: Article Affiliation country: 1560-7917.Es.2022.27.1.2101114